Konakion Mm Voor Kinderen (Phytomenadione)

Phytomenadione serves as a cofactor for the enzyme that gamma‑carboxylates glutamic acid residues on clotting factors II, VII, IX, and X. This modification enables the factors to bind calcium, a critical step for their activation in the coagulation cascade, thereby re‑establishing effective blood clot formation.

The specific dose of Konakion Mm Voor Kinderen is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and route of administration. Healthcare professionals calculate the appropriate amount to achieve the desired therapeutic effect while minimizing risk.

Safety data for phytomenadione in pregnancy and lactation are limited. The decision to use Konakion Mm Voor Kinderen during pregnancy or while breastfeeding should be made by a qualified healthcare provider after weighing potential benefits against any possible risks to the mother and child.

To order Konakion Mm Voor Kinderen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details, and necessary import documentation.

Konakion Mm Voor Kinderen contains phytomenadione, a synthetic form of vitamin K1, which is rapidly active and suitable for injectable or oral use in children. Compared with other vitamin K preparations, it offers a pediatric‑specific formulation and is approved for both deficiency bleeding and warfarin reversal, providing flexibility in clinical settings.

Store Konakion Mm Voor Kinderen at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly sealed to maintain stability until the expiration date.

Konakion Mm Voor Kinderen can be given by intramuscular, intravenous, or oral routes, as directed by the prescriber. The appropriate route and technique depend on the clinical situation, patient age, and the urgency of correcting the vitamin K deficiency.

Serious risks include anaphylactic reactions, severe allergic dermatitis, hemolysis, thrombosis, and hypotension. Patients should be monitored closely for any signs of these adverse events, and immediate medical attention is required if they occur.

Konakion Mm Voor Kinderen should not be used in individuals with known hypersensitivity to phytomenadione or any excipients in the formulation. It is also contraindicated in patients where vitamin K administration could exacerbate underlying conditions, such as certain clotting disorders, without medical supervision.